Question 1

What exactly did the federal government do on April 23, 2026?

Accepted Answer

The Department of Justice moved two narrow kinds of cannabis from Schedule I to Schedule III. The first is cannabis in an FDA-approved drug product. The second — the one that matters for most operators reading this — is cannabis sold under a state medical marijuana license.

Everything else stayed in Schedule I. Recreational. Unlicensed. Synthetic THC. Cannabis sold as food or supplements.

Three things came out of the order. A new federal registration pathway opened for state-licensed medical operators, with a 60-day window to file the easy way. The federal tax penalty under Section 280E stopped applying to state-licensed medical activity starting tax year 2026. And state-licensed medical activity now operates, federally, as a Schedule III substance instead of a Schedule I one.

Question 2

Who signed it, and why does the title "Acting Attorney General" matter?

Accepted Answer

Acting Attorney General Todd Blanche signed the order. The natural question is whether the word acting makes the order weaker. The answer is no.

An Acting AG holds the same legal authority as a confirmed one. The rescheduling power Congress gave to the office in 1970 sits with whoever holds the office at the moment of signing. Blanche held it. He used it.

The lawsuits being prepared against the order will probably mention the acting title in passing. None of them rest on it. The real legal fight is about the route the order used to make the change — not about who held the pen.

Question 3

When did it take effect, and why are people saying different dates?

Accepted Answer

Four dates are floating around. Here they are, in order, with what each one actually means.

April 22, 2026 — the order was signed. Internal date. Doesn't do anything to anybody.

April 23, 2026 — the announcement. The day the news broke. The day the industry started moving. Doesn't carry legal weight on its own.

April 28, 2026 — published in the Federal Register. This is the day the order became law. If a date matters for federal-law purposes, it's this one.

January 1, 2026 — not a date the order took effect at all. It's the start of tax year 2026, which is the full year the Section 280E tax relief covers. People confuse the two and it's an easy mix-up to make.

Two dates carry weight going forward. April 28, when the order went live. And June 27, when the 60-day window to file for federal registration the easy way closes.

Question 4

Is this a final rule or a proposed rule?

Accepted Answer

Final. Already law. Not a draft, not a proposal, not waiting on a comment period.

Most federal rules go through a process where the agency proposes a rule, takes public comment for months, considers what came in, and then issues a final version. That process didn't happen here. The order skipped it, using a different legal authority that lets the Attorney General issue a binding order directly.

That shortcut is part of why some groups are getting ready to challenge the order in court. The challenge isn't to whether the order is in force — it is — but to whether the shortcut was the right one to use. While that fight plays out, the order is the law.

Question 5

What's Executive Order 14370, and how does it connect to the order?

Accepted Answer

Executive Order 14370 was the president's instruction to the agencies. Trump signed it on December 18, 2025. It told DOJ, HHS, Treasury, and FDA to move quickly on rescheduling cannabis in a way that lined up with U.S. treaty commitments.

The executive order itself didn't reschedule anything. Presidents don't reschedule drugs. Agencies do. The EO was the directive — get this done — and the April 23 order is the agencies delivering on it.

Question 6

Did Congress pass a law? Did the President sign legislation?

Accepted Answer

No. Congress didn't vote on this. The President didn't sign a bill. No new law was passed.

This surprises people, because changing the legal status of cannabis sounds like exactly the kind of thing Congress would have to do. It isn't. Congress already did that part — back in 1970, when it passed the Controlled Substances Act and gave the Attorney General the authority to move substances between schedules administratively. Every rescheduling that has ever happened has happened that way. Congress wrote the rules of the game; the agencies play it.

What is unusual here isn't the absence of Congress. It's which path inside the agency authority got used. The standard path involves a long scientific review and a public comment period. The path used here was a faster one tied to a treaty obligation. That choice is the part being challenged in court — not the underlying authority.

Question 7

Where can I read the actual text of the order?

Accepted Answer

The official version is in the Federal Register, dated April 28, 2026. That's the version that controls if anything ever comes down to exactly what does it say.

The DEA Diversion Control Division also hosts a copy on its website, alongside the new regulations the order put in place. Treasury and the IRS have published their own separate notices on the tax side.

Question 8

What's the difference between the Final Order, the Final Rule, and the Federal Register publication?

Accepted Answer

Three names. One event.

The Final Order is the legal action — the Attorney General signing the paper that moves cannabis between schedules. That's the move itself.

The Final Rule is the package of new regulations that come along with the move. A new registration pathway. New paperwork requirements. Updates to existing rules so they fit the new schedule. The order makes the change; the rule makes the change work.

The Federal Register publication is the official document that contains both, plus the agency's written explanation of why it did what it did. It's the version everyone cites.

In conversation, people use these terms interchangeably and it's usually fine. If you ever need to point to the official one, it's the Federal Register publication.

Question 9

How was this even allowed? People keep saying "the treaty route" — what does that mean?

Accepted Answer

Most federal rules take a long time to change. The agency has to study the substance, ask experts, take public comment, weigh it all, and write a careful new rule. That whole process for cannabis got started back in 2024 — and it stalled out. The judge running it stepped aside, the proceeding sat dormant, and by early 2026 nobody was moving it forward.

So the government used a different path. A long time ago, the United States signed a worldwide agreement with most other countries about how drugs get categorized. There's a provision in U.S. law that says: if a drug needs to move so U.S. law matches what that agreement allows, the Attorney General can issue a direct order. No long study. No comment period.

That's the path they used. The reasoning: medical cannabis fits where the agreement allows medical drugs to sit. Schedule III is that spot. Move it there.

It's legal authority, real and on the books. But it's a path that was mainly built for adding restrictions to match the treaty, not for removing them. The argument that the path wasn't built for changes this large is what's going to court.

Question 10

What exactly is now in Schedule III?

Accepted Answer

Two narrow things.

First, cannabis inside an FDA-approved prescription drug. The category is small today — Epidiolex is the main product in it — but it's the legal pathway for any future cannabis-derived drug that gets through FDA approval.

Second, and this is the one that matters for most operators: cannabis sold under a state medical marijuana license. That covers the plant material, the extracts, the edibles, the topicals — anything moving through a state-licensed medical supply chain to a qualifying patient.

On the federal paperwork, drug codes 7362 (marijuana), 7353 (marijuana extract), and 7386 (naturally-derived Δ9-THC) apply depending on what an operator handles. Those are the numbers that go on DEA registration filings.

Question 11

What's still in Schedule I?

Accepted Answer

Everything the order didn't name. The two categories that moved are narrow — everything outside them stays where it was.

That includes recreational and adult-use cannabis. It includes unlicensed cannabis, even where state law allows certain unlicensed activity. It includes synthetic THC products. It includes cannabis sold as food, as a dietary supplement, or as an unapproved drug (the FDA piece — separate from how the DEA schedules it). And it includes extracts that don't fall under either the FDA-approved-drug category or a state medical license.

The leftovers are bigger than the categories that moved. That's the part the news coverage tends to miss.

Question 12

What does "marijuana subject to a state medical marijuana license" actually mean — by activity, by product, by transaction?

Accepted Answer

Three ways to read the line.

By activity: cultivation, processing, distribution, and dispensing performed under a state medical marijuana license.

By product: flower, extracts, edibles, topicals — anything produced and moved inside the licensed medical supply chain.

By transaction: transfers between state-licensed medical entities, and sales to qualifying medical patients.

The important thing to understand: the schedule status follows the license, not the plant. The same chemical compound is Schedule III when it's moving through a state-licensed medical channel, and Schedule I when it's moving through an unlicensed or recreational channel. The molecule doesn't change. The legal status does.

Question 13

What's the FDA-approved drug product category, and what products are in it?

Accepted Answer

It's the category for cannabis-derived prescription medicines that have gone through the FDA approval process.

Today there's essentially one product in it: Epidiolex, a cannabidiol oral solution prescribed for certain rare pediatric epilepsy syndromes. A handful of other cannabis-derived drugs are working their way through FDA — some closer than others. Anything that gets approved drops into this category automatically.

It's a small category right now. Long-term, it's the legal lane for any pharmaceutical-grade cannabis product.

Question 14

Did adult-use / recreational cannabis change at all?

Accepted Answer

No. Recreational cannabis is still in Schedule I. The order didn't address it.

There is a separate proceeding underway that might eventually move recreational too — the DEA hearing scheduled for June 29, 2026 is the start of it. But that's a slower process, and any rule that comes out of it won't take effect in 2026. Late 2027 is the optimistic timeline. 2028 is more realistic.

For now, recreational is where it was.

Question 15

What about cannabis sold as foods, dietary supplements, or unapproved drugs?

Accepted Answer

Still Schedule I from the DEA's side. And separately, still a problem from the FDA's side.

The FDA treats cannabis-containing products that haven't gone through drug approval as either unapproved drugs (if anyone is making health claims about them) or as products that don't fit the food and supplement categories. The rescheduling order didn't change any of that.

For an operator producing cannabis-infused food or beverages under a state medical license, the situation is layered. The product is Schedule III for federal controlled-substance purposes — because it's state-licensed medical. But it can still face FDA enforcement on a completely separate track if it's marketed in a way that triggers the FDA's drug or supplement rules. Two regulators, two frameworks, one product.

Question 16

What is Section 280E, in plain terms?

Accepted Answer

Section 280E is a federal tax rule that says any business trafficking in a Schedule I or II controlled substance can't take ordinary business deductions.

Operators can still deduct cost of goods — the actual cost of the product sold. That's a constitutional floor and it never moved. But everything else — rent, payroll, utilities, marketing, professional fees, depreciation — none of it was deductible under federal law as long as cannabis was Schedule I.

The practical effect: cannabis operators have been paying federal income tax on something close to gross profit, not net income. For a lot of operators, effective federal tax rates ran above 70 percent on book income. That's the rule the April 28 rescheduling ends for state-licensed medical operators.

Question 17

When exactly does 280E relief start for state-licensed medical operators?

Accepted Answer

The legal trigger is the rescheduling taking effect on April 28, 2026. The order is explicit: holders of state medical marijuana licenses are no longer subject to the 280E disallowance as a result of the rule.

For the return being filed, the IRS and Treasury have said the relief applies to the full 2026 tax year. Tax year 2026 is the first year an operator can take operating expense deductions under federal law.

Question 18

Why are people saying "January 1, 2026" — is that right or wrong?

Accepted Answer

Wrong as a legal date. Understandable as shorthand for the tax year.

The rescheduling order took effect April 28, 2026 — not January 1. But the IRS and Treasury have said the tax relief applies to the full 2026 tax year, which started January 1. So in terms of what it means for an operator's return, the practical answer is the full year counts.

Anyone saying the law changed January 1 is repeating a misreading. The correct statement is: the law changed April 28, and the IRS is treating the full 2026 tax year as the first year of relief.

Question 19

Is 280E relief automatic, or do operators need to claim it?

Accepted Answer

Not automatic in the sense that deductions appear on a return without action. They have to be claimed.

The legal basis exists now — the rescheduling is the trigger, and it's already done. But deductions don't happen unless they go on the return. The open question right now is exactly how to position those deductions methodologically, since the IRS hasn't issued final guidance yet on the mechanics. That's a conversation to have with a CPA before the return is filed, not after.

Question 20

Does 280E relief require DEA registration?

Accepted Answer

No. These are two separate things.

The DEA registration is an operator's federal operating credential under the new Schedule III framework. The 280E relief is a tax consequence of the rescheduling itself. The order is explicit: the 280E disallowance ends because of the rescheduling, not because of registration. An operator could have 280E relief without a federal registration. An operator could have a federal registration without it affecting 280E. They run on separate tracks.

Don't let anyone conflate the two.

Question 21

What about retroactive relief — is it real, optional, or speculative?

Accepted Answer

Speculative. Worth watching, but don't plan around it.

The order encouraged Treasury to consider giving relief for prior years when an operator was running under a state medical license. That's a suggestion, not a mandate. Treasury and IRS said on April 23 they plan to issue guidance — but as of mid-May 2026, nothing is formalized.

Plan the 2026 return assuming that year is the first year of relief. If retroactive relief eventually comes through for 2022, 2023, or 2024, that's upside. Build toward that position now if a CPA recommends it, but don't file amended returns yet.

Question 22

Should operators file amended returns? What about protective refund claims?

Accepted Answer

Don't file amended returns for prior years yet. The legal basis for a retroactive 280E deduction position doesn't exist until IRS issues guidance on it. Filing now is getting ahead of the law.

Protective refund claims are a different question. A protective claim stakes out a position before a refund opportunity expires under the statute of limitations, without requiring the claim to be fought today. For tax years 2022, 2023, and 2024 specifically — where refund windows could close before guidance arrives — it's worth a conversation with a CPA about whether a protective claim makes sense.

The line is: wait on amended returns, ask the CPA now about protective claims.

Question 23

What's the current status of IRS and Treasury guidance?

Accepted Answer

Treasury and IRS announced on April 23, 2026 that guidance is coming. As of mid-May 2026, nothing has been issued.

When it arrives, expect it to cover: confirmation that 280E doesn't apply to state-licensed medical operators for 2026 and forward, the transition period (April 28 treatment), and possibly a position on retroactive relief for prior years.

This page will be updated when guidance drops. Check the update date.

Question 24

What happens to cost-of-goods-sold treatment now that operating expenses are deductible?

Accepted Answer

Less pressure to maximize COGS.

Under 280E, operators worked hard to push as many costs as possible into cost of goods sold — because COGS was the only bucket that reduced taxable income. Some of that involved aggressive interpretations of the Section 263A inventory capitalization rules.

With operating expenses now deductible on the federal return, those costs come out either way. The incentive to push everything into COGS evaporates. Expect downward pressure on aggressive Section 263A positions in 2026, both in how operators file and possibly in how the IRS approaches it.

Question 25

Does this change state taxes?

Accepted Answer

Depends on the state. State excise and sales taxes on medical cannabis don't change because of federal rescheduling. Those are state-level decisions, independent of federal scheduling.

For state income tax: most states with cannabis programs conform in some way to the federal Internal Revenue Code. Where the state follows federal taxable income or adjusted gross income, the 280E relief that flows through on the federal return generally flows through on the state return as well. Where the state has its own decoupled cannabis-specific tax rules, the federal change may not flow through automatically.

Confirm specifics with a CPA. State conformity questions are fact-specific and the rules differ from state to state.

Question 26

What's the realistic effective-tax-rate change for a qualifying medical operator?

Accepted Answer

Substantial. Industry projections put effective rates for qualifying medical operators at roughly 20 to 30 percent post-relief, down from the 70-percent-plus range most were paying under 280E.

What an operator actually lands at depends on how expense-intensive the operation is, how COGS is treated, and entity structure. But the directional answer is a significant improvement in after-tax cash flow starting with the 2026 return.

Question 27

Are there penalties for taking deduction positions before IRS guidance is issued?

Accepted Answer

Low risk for the 2026 return, if the position is grounded in the order itself and taken in good faith.

The federal penalty rules require "substantial authority" or "reasonable basis" for a return position to avoid accuracy-related penalties. The rescheduling order is a final agency action that explicitly ends 280E's application to state-licensed medical operators. A deduction position resting on that order, applied in a reasonable way, is on solid enough ground for the 2026 return.

The risk goes up sharply if an operator files amended prior-year returns claiming retroactive relief before the IRS says that's allowed. That's the conservative line to hold.

Question 28

What does "trafficking" mean in 280E, and how does the rescheduling change that analysis?

Accepted Answer

"Trafficking" in Section 280E just means being in the business of buying or selling the substance. Courts set a low bar — it's not about volume or intent, just whether the business is in that business. State legality doesn't matter.

Before April 28, 2026: every cannabis business was trafficking in a Schedule I substance under federal law. Didn't matter if there was a state license. Federal law saw one thing.

After April 28, 2026: state-licensed medical operators are trafficking in a Schedule III substance. Section 280E doesn't cover Schedule III. So the deductions open up.

The word trafficking didn't change. The schedule did. That's the whole mechanism.

Question 29

How does 280E apply to mixed operators with both medical and recreational activity?

Accepted Answer

It depends on how clean the books separate the two.

The rescheduling moved state-licensed medical activity to Schedule III. Recreational activity stayed in Schedule I. For an operator that runs only one or the other, the answer is clean: medical operators get 280E relief, recreational operators don't.

For an operator running both — a vertically integrated MSO with medical and adult-use lines under one roof, or a state where the same entity holds licenses for both — the 280E disallowance still applies to the recreational portion of the business. The relief applies to the medical portion.

The mechanics of separating the two haven't been formally addressed by IRS guidance yet. The conservative expectation: operators will need to track and allocate revenue, COGS, and operating expenses between the medical and recreational sides with enough specificity to support a deduction position on the medical side and a disallowance on the recreational side. Some operators are already considering legal entity separation to make that allocation cleaner. That's a structural conversation to have with counsel and a CPA before the 2026 return.

If the operation is in a medical-only state, this question doesn't apply. If the operation is in a dual-program state, treat this as one of the higher-priority planning items of 2026.

Question 30

What is the DEA registration created by § 1301.13(k)?

Accepted Answer

A new category of federal registration, created specifically for operators holding a state medical marijuana license.

Before April 28, 2026, there was no federal registration pathway for a cannabis business. The DEA didn't have a box for these operators. The April 23 order created one — Section 1301.13(k) — and the DEA opened the application portal on April 29.

The state medical license is the foundation. The application uses it as conclusive proof that the state has authorized the activity. The DEA is then required to grant the federal registration unless there's a specific public-interest reason to refuse.

The registration is what gives an operator federal-law cover to operate as a Schedule III business. Everything the rescheduling opens up — banking access, federal commerce relationships, federal frameworks as they develop — flows through it.

Question 31

Who needs to register?

Accepted Answer

Any entity holding a state medical marijuana license that plans to keep manufacturing, distributing, or dispensing under federal Schedule III.

That means dispensaries, processors, growers, and transporters. Vertically integrated operations — where one entity holds multiple license types — file a separate registration for each activity type. And a separate application is required for each physical location.

If an entity holds a state medical marijuana license and intends to continue operating, it needs to register.

Question 32

Who can't register under this pathway?

Accepted Answer

Several categories are outside the lane.

Recreational-only operators. Hemp businesses operate under a separate federal framework entirely. Operators handling synthetically derived THC. Operators without a current, active state medical marijuana license. And anyone whose state license has been suspended or revoked — if the state license is gone, there's nothing to anchor the federal registration to.

The pathway is specifically for active state-licensed medical operators. If the state license isn't current, the pathway isn't open.

Question 33

When does the 60-day expedited window close?

Accepted Answer

June 27, 2026. That's 60 days from the Federal Register publication date of April 28.

For practical purposes, treat June 26 as the deadline. That's the last business day before the cutoff. Filing on June 27 is technically within the window, but leave a business day of buffer — the portal has already seen heavy traffic.

Some early coverage cited June 22. That date was wrong. The publication date was April 28; the correct deadline is June 27.

Question 34

What's the difference between filing inside the window and filing after it?

Accepted Answer

Two things an applicant gets inside the window that disappear after June 27.

First, a processing target. The DEA Administrator must make every effort to decide the application within six months. Filing by June 27 secures that commitment. Filing later means no timeline at all — standard DEA registration processing has historically run anywhere from a few months to well over a year.

Second, and more important: the right to keep operating under a state license while the federal application is pending. Filing inside the window protects continued operations. The federal rule explicitly authorizes continued manufacture, distribution, and dispensing under the state license during the review. Filing outside the window means that protection doesn't apply. During the review period, the operator would be handling a Schedule III substance without federal authorization.

Same application. Same pathway. Materially different situation depending on which side of June 27 the filing falls.

Question 35

Why is registering better than just not registering?

Accepted Answer

Three layers of better.

The window. Filing by June 27 gets a six-month processing target and the right to keep operating under the state license while the federal application is reviewed. Those two protections go away after the window closes.

What the registration itself does. Once registered, the operator has federal-law authorization to handle a Schedule III substance. The DEA must grant it unless there's a specific public-interest problem with the application. Existing state-compliant SOPs, security, and recordkeeping satisfy most federal requirements — the operator isn't double-regulated, it's regulated once with federal recognition layered on.

What it opens downstream. Banking and payment relationships that require Schedule III compliance treat DEA registration as the entry ticket. Any commerce between federally registered businesses — research arrangements, supply-chain transactions, whatever federal frameworks emerge from here — requires registration as the baseline. Every federal benefit of Schedule III flows through this registration.

One thing registration doesn't control: 280E relief. That flows from the rescheduling itself, not from registration. Don't mix the two up.

Question 36

What really happens to an operator that doesn't register?

Accepted Answer

Nobody comes to shut the operator down. The federal government has been clear that the registration process isn't intended as an enforcement net for state-licensed operators. The state license still works. Patients still come. Day to day, things look the same.

But quietly, the operator falls behind.

Banking and payment relationships that open up for registered Schedule III operators don't open. Any chain of commerce that requires registrant-to-registrant documentation is closed off. Federal frameworks built on registration as the baseline — whatever Congress, Treasury, or DEA build next — won't include the unregistered operator. And the operators next door who did register are moving into territory the unregistered one is locked out of.

And if the operator changes its mind later? It can still apply. But the window closed June 27, so it loses the six-month processing target and the right to keep operating while it waits for an answer.

The honest summary: not registering is survivable. It's also, under the new regime, the strictly worse position. The cost is paid in slow compounding losses, not in a single dramatic event.

Question 37

Is registration mandatory or optional?

Accepted Answer

Technically optional. Practically, it's the wrong frame.

The federal rule doesn't force operators to register. Nobody will fine an operator on June 28 for not having filed. But every federal benefit the rescheduling created — banking access, federal operating authorization, federal commerce relationships, whatever frameworks develop from here — requires registration. Calling it "optional" is technically accurate in the same way it's technically optional to show up for a state license renewal.

For any medical operator planning to be in business in 2027 and beyond, the meaningful choice isn't file or don't. It's file now with the window open, or file later without the protections.

Question 38

Can the DEA refuse to register an applicant?

Accepted Answer

Yes, but the bar is high and the presumption runs in the applicant's favor.

The rule says the Administrator must grant the registration unless doing so would be inconsistent with the public interest or with U.S. treaty obligations. That's a must-grant standard with narrow exceptions — not discretionary approval.

The public-interest factors the DEA looks at are things like: prior DEA history, compliance record, diversion controls, criminal history of principals. For a state-licensed dispensary or processor that's been in good standing, those factors point toward approval.

Refusals will happen, but they'll be based on specific concerns about a specific applicant — not blanket discretion to turn away state-licensed operators.

Question 39

What does "shall grant unless inconsistent with the public interest" actually mean?

Accepted Answer

It means the default answer is yes, and the DEA has to have a real reason to say no.

Most federal approvals work the other way: the applicant has to prove they deserve it. This one flips that. The rule puts the burden on the agency. If the DEA wants to deny an application, it has to point to something specific — a compliance problem, a criminal history, a diversion risk — and explain why that specific thing makes approval inconsistent with the public interest.

For an operator that's been running clean under a state license, "inconsistent with the public interest" is a difficult standard for the DEA to meet. That's by design.

Question 40

What's the difference between Form 224 and Form 225?

Accepted Answer

Two different forms for two different roles.

Form 224 is for dispensers — the retail side, selling to qualifying patients. A state-licensed dispensary uses this form.

Form 225 is for manufacturers and distributors. That covers growers, processors, and transporters.

If an operation is vertically integrated — growing, processing, and dispensing — it files both. One 225 for the upstream activities, one 224 for the dispensing side. Same legal entity, two separate registrations.

Question 41

Do operators file separately for each location, each entity, or each activity type?

Accepted Answer

Both location and activity type. Each physical address gets its own application. Each activity type (grower, processor, transporter, dispenser) gets its own registration.

Same legal entity, multiple registrations. A single licensee with a grow site, a processing facility, and three dispensary locations files five separate applications — one for the grow, one for processing, three for the dispensaries.

The registration scope at each location can't go beyond what the state medical license at that location allows.

Question 42

How long does the application take to process?

Accepted Answer

Inside the window: the DEA must make every effort to decide within six months. Applications filed by June 27 are targeting decisions by approximately late October or early November 2026.

Outside the window: no timeline. Standard DEA processing has historically ranged from a few months to well over a year. There's no commitment, no queue priority, and no during-pendency operating protection while waiting.

Question 43

Can operators keep operating while the federal application is being reviewed?

Accepted Answer

Yes — if filed inside the window.

The rule explicitly authorizes continued operation under the state license during the review of the federal application, for operators who filed by June 27. They're covered. Keep running.

Filing after the window closes means that protection doesn't apply. Operating during the review period of a late-filed application means handling Schedule III cannabis without a federal registration — which is federally unauthorized handling of a controlled substance. The legal gap is real even if enforcement is unlikely.

Question 44

What happens to the federal registration if the state medical license lapses?

Accepted Answer

The federal registration automatically suspends the moment the state license is suspended, revoked, or expires. There's no grace period. The federal authorization goes away when the state authorization goes away.

Reinstatement of the federal registration follows reinstatement of the state license, but it's not automatic — there's a notification process to go through.

The practical implication: the state license renewal calendar needs to be on the radar before the federal renewal calendar. State first, always. A lapsed state license is the fastest way to lose the federal registration.

Question 45

How long is a registration valid before renewal?

Accepted Answer

Depends on activity type.

Dispensaries renew every three years. Manufacturers and distributors renew annually. Renewal cycles run from the date the registration is granted, not the date it was applied for.

Factor this into the compliance calendar alongside the state renewal schedule. The two run on different timelines and both need to stay current.

Question 46

What are the fees, and how often are they paid?

Accepted Answer

Application fee: $794 per location, paid at filing. Covers every activity type at that location.

Renewal fees: manufacturers pay approximately $3,699 per year; distributors approximately $1,850 per year; dispensaries approximately $888 per three-year cycle — roughly $296 per year equivalent.

Payment at filing is currently processed through PayPal. Additional payment methods are reportedly being added. Confirm current fee amounts on the DEA Diversion Control fee schedule before filing — the numbers are subject to periodic adjustment and these figures reflect the schedule as of mid-May 2026.

Question 47

Where is the portal and what's needed to access it?

Accepted Answer

The DEA Diversion Control Division portal at deadiversion.usdoj.gov. Standard browser, no special software.

If the entity doesn't already have a DEA registrant account — most cannabis operators won't — a new account has to be created before starting the application. Supporting documents upload as PDFs.

The portal opened April 29, 2026. It has already seen heavy traffic. Don't leave the filing for the last day before June 27.

Question 48

What information do operators need before starting?

Accepted Answer

More than expected. Treat the prep phase as a one-to-two-week project, not a same-day task.

At minimum, have ready before opening the portal:

- Entity legal name and any DBAs
- EIN
- Business address for each location being filed
- Organization type and ownership structure, including any changes in ownership history
- Current state medical license documentation — license number, expiration date, clean PDF of the official license
- List of suppliers being sourced from, with their DEA registration numbers if they have them (most won't yet)
- Names and biographical detail for everyone who will have access to controlled substances at the location — including Social Security numbers and criminal history
- SOPs: cultivation, processing, security, inventory, recordkeeping, disposal — whatever applies to the license type
- Payment information for the $794 application fee

Question 49

What are the seven sections of the application?

Accepted Answer

The application has seven sections.

1. Personal/Business Information. Entity name, EIN, address, organization type, ownership history, prior DEA registrations.

2. Activity. What substances the operator handles. State-licensed medical marijuana is drug codes 7362 (marijuana), 7353 (marijuana extract), and 7386 (naturally-derived Δ9-THC), depending on what's handled. There's also an explicit yes/no question about whether the operator handles recreational marijuana — answer honestly.

3. State License(s). State medical license number and expiration date.

4. Liability Questions. Five questions covering criminal history, federal licensure history, professional licensure history, and — the one that matters most — whether anyone in the ownership or operation has previously handled a controlled substance without a DEA registration authorizing it. Most established operators answer yes. Read the disclosure section of this FAQ before answering this one.

5. Compliance Information. Supplier list with DEA numbers, SOPs by activity type, and personnel disclosures for everyone with access to controlled substances.

6. Payment. The $794 application fee.

7. Submission. Final review and certification that everything submitted is accurate, under penalty of federal law.

Question 50

What state-license documentation needs to be attached?

Accepted Answer

A current, unexpired copy of the state medical marijuana license. Most state licenses are issued digitally; a clean PDF of the official license document is what the portal accepts.

The license must be in the name of the entity that is filing. If the license is held under a different legal name than the one applying — because of an acquisition, a restructuring, or a name change — sort that out before filing. The DEA uses the state license as conclusive evidence of authorization. If the names don't match, that evidence doesn't hold.

Question 51

How do operators identify and disclose suppliers?

Accepted Answer

Section 5 asks operators to identify medical marijuana suppliers by name and, where they have one, their DEA registration number.

Here's the practical problem: most suppliers in the early window won't have federal registrations yet, because everyone is filing at the same time. Where a supplier doesn't have a DEA number yet, use their state license information instead.

If the supplier list changes after approval, there are ongoing update obligations. It's not a one-time disclosure.

Question 52

What SOPs are required as part of the filing?

Accepted Answer

The application asks whether operators have SOPs for each activity conducted — cultivation, manufacturing, packaging and labeling, dispensing, inventory, recordkeeping, security, disposal, and personnel access controls.

The answer for most state-licensed medical operators is yes. State medical program compliance has required documented procedures in most of these areas for years.

The important distinction: operators are identifying that SOPs exist, not uploading the full text. SOPs need to be on the shelf and available for inspection — not attached to the application.

State-law SOPs are accepted where they meet federal minimums. Most mature state-compliant SOP packages do. Where they don't — primarily in areas where state law is silent and federal law has specific requirements — a federal addendum may be needed. That's a relatively narrow gap for most operators.

Question 53

What personnel disclosures are required, and for whom?

Accepted Answer

For every person who will have access to controlled substances at the registered location: full legal name, biographical detail, Social Security number, any individually-held DEA registration numbers, and criminal history.

The "who" is broader than just security staff or compliance officer. It covers anyone in the chain of custody at the location — which in a dispensary setting, for example, includes anyone who handles product. In a grow or processing facility, it includes anyone with access to the plant area.

This is one of the sections that takes time to assemble. Start the personnel roster early in the prep phase.

Question 54

What background-check material is required?

Accepted Answer

Criminal history is self-disclosed in the application for each person listed in the personnel section. The operator reports it; the DEA then conducts its own background investigation as part of the review.

State background-check documentation — whatever was collected when those employees were hired — should be retained on-site and available for inspection, but it generally doesn't get uploaded with the federal application.

Be accurate in what's self-disclosed. The DEA will verify it. Discrepancies between what's reported and what the investigation finds are a more serious problem than the underlying history itself.

Question 55

How is payment handled?

Accepted Answer

The $794 application fee is currently paid through PayPal at the time of submission. Additional payment methods are reportedly being added to the portal, but PayPal is what's available now.

Renewal fees — when they come due — use existing DEA fee-payment infrastructure, which supports ACH and check in addition to online payment.

The $794 is per location. An operator filing for three dispensary locations files three applications and pays three fees.

Question 56

Can the application be amended after submission?

Accepted Answer

Yes, through the DEA's standard modification process. But don't treat post-submission amendment as a substitute for a clean initial filing.

Minor corrections go through the registrant portal. Material changes — ownership structure, activity scope, location address — require a formal modification and restart certain parts of the review. An amendment is not a do-over; it adds process.

Get it right the first time. The prep work in the two weeks before filing is how that happens.

Question 57

What if an operation holds licenses in multiple states?

Accepted Answer

Separate filings for each state, each location, each activity type. There's no consolidated multi-state registration. An operator in Oklahoma and Florida files in both states separately, with separate state-specific license documentation, separate personnel disclosures where personnel differ, and separate fees per location.

This is mostly a question for MSOs and operators thinking about expansion. For single-state operators, the answer is simple: one state, one set of filings.

Question 58

If an operator is vertically integrated, do they file one application or several?

Accepted Answer

Several. One legal entity, multiple registrations.

Each activity type — grower, processor, distributor, dispenser — requires its own registration, even under the same entity. Each physical location requires its own application.

A fully vertical operation with a single grow site, a single processing and distribution facility, and three dispensary locations files five registrations: one for the grow (Form 225), one for processing/distribution (Form 225), and three dispensary registrations (Form 224, one per location). Five applications, five fees.

The scope of each registration is bounded by the state license at that location. A Form 225 filed on a grower license can't be used to authorize dispensing.

Question 59

What's the timeline from submission to decision?

Accepted Answer

Early filers — submitted by June 27, 2026: six-month processing target. Plan for decisions in the late October to early November 2026 range, with some variation depending on how complex the application is.

During that period, if the application was filed inside the window, the operator is authorized to keep operating under the state license. The timeline is less operationally critical for these filers than for late filers, because they have cover while they wait.

Late filers — submitted after June 27: no timeline commitment. Historical DEA processing has ranged from a few months to well over a year. No during-pendency operating protection. The wait is both indefinite and legally exposed.

Question 60

Section 4 asks whether anyone in ownership has previously handled controlled substances without DEA authorization. How should that be answered honestly?

Accepted Answer

Honestly. Yes is the right answer for most established operators.

Here's the reasoning. Before April 28, 2026, every state-licensed cannabis activity in the United States was, federally, handling of a Schedule I substance without a DEA registration. That's what the law said and that's what every state-licensed medical operator was doing, regardless of how clean the state-side compliance was. The federal text didn't distinguish between an operator running clean under state license and an operator running an illegal grow.

So if the operator has been operating in a state medical program for any meaningful period before April 28, the truthful answer to the question is yes.

False or incomplete answers are federal crimes under 18 U.S.C. § 1001 and 21 U.S.C. § 843. The DEA verifies what's disclosed. Getting caught lying is much worse than the underlying history. DOJ has signaled it does not intend to use this disclosure as an enforcement tool against state-licensed operators — that's why the question is survivable. It's not why the question can be skipped or shaded.

This is the question on the application most worth running past counsel before submitting. The yes-answer narrative matters.

Question 61

Could the application itself create federal-law exposure?

Accepted Answer

In a narrow technical sense, yes. The application puts on the federal record activity that was, before April 28, federally unauthorized handling of a controlled substance. That record exists now in a way it didn't before.

The exposure is heavily mitigated by three things working in operators' favor. First, DOJ has explicitly said it does not intend to use this process to enforce against state-licensed operators. Second, the rescheduling itself prospectively legalizes the activity going forward — the conduct being disclosed is now permissible activity for a state-licensed medical operator. Third, the rule's structural presumption in favor of granting registration means the disclosure is the path to federal cover, not a trap.

The exposure is not zero. Operators with unusual fact patterns — prior federal investigations, criminal records of principals, activity that went beyond what state license authorized — face higher residual risk and should engage counsel before filing. For the typical operator running clean under a state medical license, the disclosure carries the protection of the broader regulatory design around it.

Question 62

Has DOJ given any signal about how it will use disclosed information?

Accepted Answer

Yes — multiple signals, all pointing the same direction.

The rule preamble itself indicates DOJ does not intend the registration process as an enforcement tool against state-licensed activity. Acting AG Blanche's statements at the time of signing reinforced the same point. And the structural design of Section 1301.13(k) — cooperative federalism with the state, automatic suspension tied to the state license, the presumption of granting registration — is consistent with a posture of integration rather than enforcement.

None of these signals are legally binding. They're policy, not law. A future administration could take a different posture toward the same disclosed information. The signals are reasons to file with confidence; they aren't guarantees.

Question 63

Are there safe-harbor or non-prosecution assurances? Are they binding?

Accepted Answer

No formal safe harbors. No non-prosecution agreements. The protections for state-licensed operators come from two places: the rescheduling itself, and DOJ's enforcement priorities.

The rescheduling is structural and durable. It changed federal law and the federal characterization of state-licensed medical activity. That protection isn't going anywhere short of the order being overturned in court or repealed by Congress.

Enforcement priorities are discretionary. They can shift with an administration change. Today's posture is favorable to state-licensed operators; the same posture is not guaranteed forward.

Operators who want belt-and-suspenders protection beyond the structural protections sometimes seek individualized opinions of counsel, or in unusual cases, pre-filing consultation with DOJ. Those are case-by-case calls for operators with specific concerns, not standard practice.

Question 64

What information from the application is publicly available?

Accepted Answer

Limited registrant information shows up in the DEA's public registrant database: name, address, DEA number, registration type, activity, expiration date. That's the standard transparency for any DEA registrant.

The substantive application content — financial information, personnel disclosures, criminal histories, ownership detail, supplier lists — is not generally public. It sits inside the agency.

That said, it isn't locked away. Information in the application can be reached through specific legal processes: FOIA requests (subject to redactions), subpoenas in litigation, regulatory inquiries, congressional oversight. The application should be treated as a document that may eventually be examined by parties beyond DEA review staff — not as a confidential filing.

FAQ

The April 2026 rescheduling

Your 2026 tax position

Should you register?

Filling out the application

Life as a federal registrant

Banking, capital & valuation

Looking ahead